Combination therapy for advanced kidney cancer after first-line treatment
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced clear cell kidney cancer that cannot be removed by surgery or has spread.
- You have received at least one prior systemic treatment (for Part 1) or had anti-PD-1/PD-L1 therapy as your first treatment (for Part 2).
- You are 19 years or older.
- You have at least one tumor that can be measured on scans.
- Your overall health is good (ECOG performance status 0 or 1).
- Your blood counts, kidney function, and liver function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This Phase 1 trial tests a new cell therapy called LNK001 in patients with advanced clear-cell kidney cancer that has progressed despite prior immunotherapy and targeted drugs. The therapy is designed to recognize and attack cancer cells by targeting a protein called CAIX.
This trial tests a new combination of two drugs (envafolimab and axitinib) as the first treatment for advanced kidney cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.